Brands of Serratiopeptidase in Kenya
Emanzen Forte,Emcure Pharmaceuticals Ltd
MODE OF ACTION:
Serratiopeptidase reduces pain and swelling without inhibiting prostaglandins and has no gastrointestinal adverse effects. It also acts by enhancing blood circulation due to proteolytic effect, removing damaged and denatured proteins and cellular debris, and modulating inflammatory cytokines.
Facial swelling after surgery to clear the sinuses.
Insufficient Evidence for
Chronic bronchitis. Developing research suggests that serrapeptase can significantly reduce coughing and thin secretions in people with chronic bronchitis after about 4 weeks of treatment.
Sinus pain (sinusitis). Early research suggests that people with sinusitis who take serrapeptase have significantly reduced pain, nasal secretions, and nasal obstruction after 3-4 days of treatment.
Hoarseness (laryngitis). Early research suggests that serrapeptase can significantly reduce pain, secretions, difficulty swallowing, and fever in people with laryngitis after 3-4 days of treatment.
Sore throat (pharyngitis). Early research suggests that serrapeptase can significantly reduce pain, secretions, difficulty swallowing, and fever in people with sore throat after 3-4 days of treatment.
Carpel tunnel syndrome.
Pus accumulation (empyema).
Fibrocystic breast disease.
Inflammatory bowel disease (IBD) including ulcerative colitis and Crohn’s disease.
DOSAGE AND ADMINISTRATION
The usual adult dosage of serrapeptase is 10 mg 3 times daily (range, 15 to 60 mg/day) 2 hours after meals. Serrapeptase has been taken for 1 to 2 weeks as an anti-inflammatory agent and up to 4 weeks as a mucolytic agent.
Serrapeptase might decrease blood clotting. Therefore, taking serrapeptase along with medications that also slow clotting might increase the chances of bruising and bleeding.
Serrapeptase was well tolerated in short-term clinical trials, but long-term safety has not been evaluated. Rare, serious adverse effects reported with serrapeptase include eosinophilic pneumonitis, bullous pemphigoid, hemorrhage in a patient with Behcet disease, and possibly Stevens-Johnson syndrome.
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, email@example.com or clicking below button:
Clinical | Pharmacokinetic data
Routes of Administration: Oral
Bioavailability: Not Available
Onset of Action:
Elimination Half life:
Legal Status | Dosage forms & Strengths
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
Dosage Forms | Strengths:
- Bhagat, Shivani, Monika Agarwal, and Vandana Roy. “Serratiopeptidase: a systematic review of the existing evidence.” International Journal of Surgery 11.3 (2013): 209-217.
- Mecikoglu, Mete, et al. “The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infection.” JBJS 88.6 (2006): 1208-1214.
- Chopra, D., et al. “A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model.” International journal of oral and maxillofacial surgery 38.4 (2009): 350-355.